This may be attributed to p95-HER2 and HER3 driven signaling, as reported previously for association with aggressive HER2-positive BC.38,39 We also confirmed the drug resistant nature of HER2 DDMs in vitro and in vivo using orthotopic mouse model. The gene discussed is ERBB3; the disease is breast cancer.